

2023-10-10

Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study

Aldred, J

<https://pearl.plymouth.ac.uk/handle/10026.1/21770>

10.1007/s40120-023-00554-w

Neurology and Therapy

Springer Science and Business Media LLC

All content in PEARL is protected by copyright law. Author manuscripts are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.



CORRECTION

Correction: Continuous Subcutaneous Foslevodopa/ Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study

Jason Aldred · Eric Freire-Alvarez · Alexander V. Amelin · Angelo Antonini ·
Bruno Bergmans · Filip Bergquist · Manon Bouchard · Kumar Budur · Camille Carroll ·
K. Ray Chaudhuri · Susan R. Criswell · Erik H. Danielsen · Florin Gandor · Jia Jia ·
Thomas E. Kimber · Hideki Mochizuki · Weining Z. Robieson · Amy M. Spiegel ·
David G. Standaert · Saritha Talapala · Maurizio F. Facheris · Victor S. C. Fung

Published online: October 10, 2023
© The Author(s) 2023

Correction: Neurol Ther
<https://doi.org/10.1007/s40120-023-00533-1>

In the sentences beginning ‘At baseline,...’ and ‘The reduction of early morning...’ in the section ‘Efficacy’ under the heading ‘Results’ in this article, the n/N values ‘129/238, 20/139,

The original article can be found online at <https://doi.org/10.1007/s40120-023-00533-1>.

J. Aldred (✉)
Selkirk Neurology and Inland Northwest Research,
610 S Sherman St, Spokane, WA 99202, USA
e-mail: J.Aldred@selkirkneurology.com

E. Freire-Alvarez
Neurology Department, University General Hospital
of Elche, Carrer Almazara, 11, 03203 Elche, Spain

A. V. Amelin
Department of Neurology and Neurosurgery, Pavlov
First Saint Petersburg State Medical University,
Ulitsa L'va Tolstogo, 6-8, St. Petersburg 197022,
Russia

A. Antonini
Parkinson and Movement Disorders Unit,
Department of Neuroscience, Padua University, Via
VIII Febbraio, 2, 35122 Padua, Italy

B. Bergmans
Department of Neurology, AZ St-Jan Brugge-
Oostende AV, Ruddershove 10, 8000 Brugge,
Belgium

25/125 and 56/125’ were incorrect and the correct sentences should have read as follows:

At baseline, 77.7% ($n/N = 129/166$) of patients experienced morning akinesia, which decreased to 19.2% ($n/N = 20/104$) at week 26, and 27.8% ($n/N = 25/90$) at week 52. The reduction of early morning “Off” time was accompanied by a marked increase in the proportion of patients reporting “On” time without dyskinesia on awakening (62.2%; $n/N = 56/90$ at

B. Bergmans
Department of Neurology, Ghent University
Hospital, Corneel Heymanslaan 10, 9000 Ghent,
Belgium

F. Bergquist
Department of Pharmacology, University of
Gothenburg, Universitetsplatsen 1, 405 30
Gothenburg, Sweden

M. Bouchard
Clinique Neuro-Lévis, 1190 A Rue de Courchevel
#301, Lévis, QC G6W 0M5, Canada

K. Budur · J. Jia · W. Z. Robieson · A. M. Spiegel ·
S. Talapala · M. F. Facheris
AbbVie Inc., 1 N. Waukegan Road, North Chicago,
IL 60064, USA

C. Carroll
Faculty of Health, University of Plymouth, Drake
Circus, Plymouth PL4 8AA, UK

week 52) (Fig. 3).

In the sentence beginning ‘The reduction of “Off” time is particularly exemplified by...’ under the heading “Discussion”, the value ‘(changed from 17.5% at baseline to 63.0% at week 52)’ should have read ‘(changed from 17.5% at baseline to 62.2% at week 52).’

The original article has been corrected.

Open Access. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit

to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

K. R. Chaudhuri
Parkinson’s Foundation International Centre of Excellence, King’s College Hospital, Denmark Hill, London SE5 9RS, UK

K. R. Chaudhuri
King’s College Institute of Psychiatry, Psychology and Neuroscience, 16 De Crespigny Park, London SE5 8AF, UK

S. R. Criswell
Department of Neurology, Washington University in St. Louis, 1 Brookings Dr, St. Louis, MO 63130, USA

E. H. Danielsen
Department of Neurology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200 Aarhus, Denmark

F. Gandor
Movement Disorders Hospital, Straße Nach Fichtenwalde 16, 14547 Beelitz-Heilstätten, Germany

F. Gandor
Department of Neurology, Otto-Von-Guericke University Magdeburg, Universitätspl. 2, 39106 Magdeburg, Germany

T. E. Kimber
Department of Neurology, Royal Adelaide Hospital, Port Road, Adelaide, SA 5000, Australia

T. E. Kimber
Department of Medicine, University of Adelaide, 4 North Terrace, Adelaide, SA 5000, Australia

H. Mochizuki
Department of Neurology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan

D. G. Standaert
Department of Neurology, Heersink School of Medicine, University of Alabama at Birmingham, 1670 University Blvd, Birmingham, AL 35233, USA

V. S. C. Fung
Movement Disorders Unit, Westmead Hospital, Cnr Hawkesbury Road and Darcy Rd, Westmead, NSW 2145, Australia

V. S. C. Fung
Faculty of Medicine and Health, Sydney Medical School, University of Sydney, Sydney, NSW 2006, Australia